MedCap’s Business Area Specialty Pharma Acquires XGX Pharma

MedCap’s wholly owned subsidiary, Unimedic Pharma AB, has signed an agreement to acquire XGX Pharma ApS (“XGX”) in Denmark.

XGX is a fast-growing specialty pharma company with a pipeline of new products. Currently, XGX’s has 7 products on the market, primarily in the Nordics. The pipeline consists of 20 niche products in either late-stage development or registration phase. Expected product launches for this pipeline will be during the coming years. XGX’s net sales during the last 12 months amounted to 51m DKK, a growth of 91% compared to the same period previous year. The EBITDA margin for the last 12 months was 35%.

The acquisition of XGX positions Unimedic as one of the leading Nordic specialty pharma companies with higher profitability, organic growth and a broad pipeline of niche products. Many of the pipeline products are also own products, which will offer good out-licensing opportunities outside the Nordic countries.

Anders Larnholt, Head of Business Area Specialty Pharma and Chairman of Unimedic comments the acquisition: ”With the addition of XGX, we can take the next step with Unimedic. We add scale in Unimedic’s home markets and a pipeline that will offer strong growth opportunities. I’m especially impressed by both team’s expertise and entrepreneurial mindset, and I look forward to what we can achieve together”.

Jens-Nikolaj Schøier, CEO of XGX, comments the transaction: "With this transaction, Unimedic recognizes all that has been created at XGX during the last 7+ years, and in particular the quality of key products and pipeline. We look forward to working closely together with Unimedic."

The purchase price comprises an initial cash payment of 135 million DKK at closing for 100% of the company's shares, with a potential additional payment of up to 140 million DKK contingent upon the gross profit growth in 2025 and 2026.

The acquisition is subject to FDI (Foreign Direct Investment) clearance in Denmark. If approved, the acquisition is expected to close during the third quarter of 2025.

This disclosure contains information that MedCap AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person, on 25-06-2025 07:30 CET.

For more information, contact:

Anders Dahlberg, CEO, Mobile 46 704 269 262,  e-mail anders.dahlberg@medcap.se